Patents by Inventor Steven H. Spergel

Steven H. Spergel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS
    Publication number: 20250074909
    Abstract: Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Application
    Filed: October 28, 2024
    Publication date: March 6, 2025
    Inventors: Junqing Guo, Amy C. Hart, John E. Macor, Michael E. Mertzman, William J. Pitts, Steven H. Spergel, Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Jie Chen, Carolyn Diane Dzierba, Guanglin Luo, Jianliang Shi, Sing-Yuen Sit
  • Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha
    Patent number: 12240840
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: March 4, 2025
    Assignee: Bristol-Myers Squibb Company
    Inventors: Steven H. Spergel, William J. Pitts, Michael E. Mertzman, Ryan M. Moslin, Trevor C. Sherwood, John L. Gilmore, Alaric J. Dyckman
  • SUBSTITUTED HETEROCYCLIC COMPOUNDS
    Publication number: 20250066322
    Abstract: There are disclosed compounds of the following formula (I): or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.
    Type: Application
    Filed: May 13, 2022
    Publication date: February 27, 2025
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: MICHAEL EDWARD MERTZMAN, RYAN M. MOSLIN, STEVEN H. SPERGEL, KARIN IRMGARD WORM
  • TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20240425505
    Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Application
    Filed: August 28, 2024
    Publication date: December 26, 2024
    Inventors: Guanglin Luo, Jie Chen, Carolyn Diane Dzierba, David B. Frennesson, Junqing Guo, Amy C. Hart, Xirui Hu, Michael E. Mertzman, Matthew Reiser Patton, Jianliang Shi, Steven H. Spergel, Brian Lee Venables, Yong-Jin Wu, Zili Xiao, Michael G. Yang
  • Aminotriazolopyridines as kinase inhibitors
    Patent number: 12157733
    Abstract: Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Grant
    Filed: December 9, 2020
    Date of Patent: December 3, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Junqing Guo, Amy C. Hart, John E. Macor, Michael E. Mertzman, William J. Pitts, Steven H. Spergel, Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Jie Chen, Carolyn Diane Dzierba, Guanglin Luo, Jianliang Shi, Sing-Yuen Sit
  • Triazolopyridinyl compounds as kinase inhibitors
    Patent number: 12110290
    Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Grant
    Filed: July 6, 2023
    Date of Patent: October 8, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guanglin Luo, Jie Chen, Carolyn Diane Dzierba, David B. Frennesson, Junqing Guo, Amy C. Hart, Xirui Hu, Michael E. Mertzman, Matthew Reiser Patton, Jianliang Shi, Steven H. Spergel, Brian Lee Venables, Yong-Jin Wu, Zili Xiao, Michael G. Yang
  • SUBSTITUTED HETEROCYCLIC COMPOUNDS
    Publication number: 20240317718
    Abstract: There are disclosed compounds of the following formula (I) or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.
    Type: Application
    Filed: May 13, 2022
    Publication date: September 26, 2024
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: STEVEN H. SPERGEL, RYAN M. MOSLIN, MICHAEL EDWARD MERTZMAN, SHOSHANA L. POSY, SIRISH KAUSHIK LAKKARAJU, JOSEPH A. TINO, ZILI XIAO, CHUNJIAN LIU, JAMES LIN
  • SUBSTITUTED HETEROCYCLIC COMPOUNDS
    Publication number: 20240270723
    Abstract: There are disclosed compounds of the following formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.
    Type: Application
    Filed: May 13, 2022
    Publication date: August 15, 2024
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: STEVEN H. SPERGEL, MICHAEL EDWARD MERTZMAN
  • SUBSTITUTED HETEROCYCLIC COMPOUNDS
    Publication number: 20240190829
    Abstract: There are disclosed compounds of the following formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.
    Type: Application
    Filed: November 30, 2023
    Publication date: June 13, 2024
    Inventors: Steven H. Spergel, Ryan M. Moslin, Michael Edward Mertzman, Joseph A. Tino, Shoshana L. Posy, Sirish Kaushik Lakkaraju, Zili Xiao, James Kempson
  • SUBSTITUTED HETEROCYCLIC COMPOUNDS
    Publication number: 20240124421
    Abstract: There are disclosed compounds of the following formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.
    Type: Application
    Filed: December 14, 2023
    Publication date: April 18, 2024
    Inventors: Steven H. Spergel, Ryan M. Moslin, Michael Edward Mertzman
  • TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20240109888
    Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Application
    Filed: July 6, 2023
    Publication date: April 4, 2024
    Inventors: Guanglin Luo, Jie Chen, Carolyn Diane Dzierba, David B. Frennesson, Junqing Guo, Amy C. Hart, Xirui Hu, Michael E. Mertzman, Matthew Reiser Patton, Jianliang Shi, Steven H. Spergel, Brian Lee Venables, Yong-Jin Wu, Zili Xiao, Michael G. Yang
  • Substituted heterocyclic compounds
    Patent number: 11884650
    Abstract: There are disclosed compounds of the following formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: January 30, 2024
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Steven H. Spergel, Ryan M. Moslin, Michael Edward Mertzman
  • Substituted heterocyclic compounds
    Patent number: 11866414
    Abstract: There are disclosed compounds of the following formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: January 9, 2024
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Steven H. Spergel, Ryan M. Moslin, Michael Edward Mertzman, Zili Xiao
  • Triazolopyridinyl compounds as kinase inhibitors
    Patent number: 11767322
    Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Grant
    Filed: October 18, 2021
    Date of Patent: September 26, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guanglin Luo, Jie Chen, Carolyn Diane Dzierba, David B. Frennesson, Junqing Guo, Amy C. Hart, Xirui Hu, Michael C. Mertzman, Matthew Reiser Patton, Jianliang Shi, Steven H. Spergel, Brian Lee Venables, Yong-Jin Wu, Zili Xiao, Michael G. Yang
  • AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CONDITIONS RELATED TO THE MODULATION OF IL-12, IL-23 AND/OR IFN-ALPHA
    Publication number: 20230020273
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: October 28, 2019
    Publication date: January 19, 2023
    Inventors: Steven H. Spergel, William J. Pitts, Michael E. Mertzman, Ryan M. Moslin, Trevor C. Sherwood, John L. Gilmore, Alaric J. Dyckman
  • SUBSTITUTED HETEROCYCLIC COMPOUNDS
    Publication number: 20220411384
    Abstract: There are disclosed compounds of the following formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.
    Type: Application
    Filed: May 13, 2022
    Publication date: December 29, 2022
    Inventors: Steven H. Spergel, Ryan M. Moslin, Michael Edward Mertzman, Joseph A. Tino, Shoshana L. Posy, Sirish Kaushik Lakkaraju, Zili Xiao, James Kempson
  • SUBSTITUTED HETEROCYCLIC COMPOUNDS
    Publication number: 20220388987
    Abstract: There are disclosed compounds of the following formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.
    Type: Application
    Filed: May 13, 2022
    Publication date: December 8, 2022
    Inventors: Steven H. Spergel, Ryan M. Moslin, Michael Edward Mertzman
  • AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
    Publication number: 20220356180
    Abstract: Compounds having the following formula I. or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: April 29, 2021
    Publication date: November 10, 2022
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S. Tokarski, Amit Kumar, Douglas G. Batt, Shuqun Lin, Chunjian Liu, Steven H. Spergel, Yanlei Zhang, Qingjie Liu
  • AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS
    Publication number: 20220315580
    Abstract: Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Application
    Filed: December 9, 2020
    Publication date: October 6, 2022
    Inventors: Junqing Guo, Amy C. Hart, John E. Macor, Michael E. Mertzman, William J. Pitts, Steven H. Spergel, Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Jie Chen, Carolyn Diane Dzierba, Guanglin Luo, Jianliang Shi, Sing-Yuen Sit
  • Aminoimidazopyridazines as kinase inhibitors
    Patent number: 11440913
    Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: September 13, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael E. Mertzman, Carolyn Diane Dzierba, Jason M. Guernon, Amy C. Hart, Guanglin Luo, John E. Macor, William J. Pitts, Jianliang Shi, Steven H. Spergel